Tg Therapeutics's 15-minute chart shows RSI Oversold and KDJ Golden Cross.

Tg Therapeutics' 15-minute chart has recently triggered a RSI Oversold and KDJ Golden Cross signal, which occurred on August 26, 2025 at 12:00. This indicates that the stock price has experienced a rapid decline, falling below its fundamental support level. Furthermore, the momentum of the stock price is shifting towards the upside, suggesting a potential increase in value.

On August 26, 2025, at 12:00, TG Therapeutics' (TGTX) 15-minute chart triggered a Relative Strength Index (RSI) Oversold signal and a KDJ Golden Cross, indicating a potential shift in the stock's momentum. This development follows a recent decline in the stock price, which fell below its fundamental support level, suggesting a potential increase in value.

The RSI Oversold signal indicates that the stock has been oversold, meaning it has experienced a rapid decline in price. The KDJ Golden Cross signal, which occurs when the K line crosses above the D line on the KDJ indicator, suggests that the momentum of the stock price is shifting towards the upside. This combination of signals can indicate a potential buying opportunity for investors.

In addition to the technical signals, TG Therapeutics reported a quarterly revenue of $141.15 million in Q2'25, which was below analyst estimates of $147.76 million. The company also missed earnings expectations with an EPS of $0.17. However, the company has raised its full-year guidance for Briumvi US net product revenues to $570M-$575M, indicating potential growth in the future.

The stock received an upgrade to a "hold" rating by The Goldman Sachs Group, with an average target price of $46.25. The company's Briumvi drug is still on track to reach blockbuster status, with analyst estimates for revenues reaching $1B by 2027. The company is also running a phase 3 trial on an improved dosing regime of intravenous Briumvi, which could help grow revenues further.

Institutional investors own 58.58% of the company's stock, with 1832 Asset Management L.P. owning approximately 0.93% of the company worth $58.5 million. Other hedge funds and institutional investors have also bought and sold shares of the company. Vermillion Wealth Management Inc. bought a new position in TG Therapeutics during the 4th quarter worth approximately $30,000, while NBC Securities Inc. raised its holdings in TG Therapeutics by 82,300.0% during the 1st quarter.

The stock has a current ratio of 3.86, a quick ratio of 2.96, and a debt-to-equity ratio of 0.89. The company has a market capitalization of $4.53 billion, a price-to-earnings ratio of 77.11, and a beta of 1.95. The stock has a 50-day simple moving average of $33.95 and a 200-day simple moving average of $35.69.

While the stock has experienced a decline in recent months, the combination of technical signals and potential growth in the future could indicate a potential buying opportunity for investors. However, investors should conduct their own research and consider their risk tolerance before making any investment decisions.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-tg-therapeutics-inc-tgtx-position-decreased-by-1832-asset-management-lp-2025-08-23/
[2] https://seekingalpha.com/article/4814885-tg-therapeutics-looking-for-stimulus-for-turnaround